Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report by State

Non-Hodgkin Lymphoma (Late Stage^), 2015-2019

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Name

Explanation of Column Headers

Objective - The objective of *** is from the Healthy People 2020 project done by the Centers for Disease Control and Prevention.

Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Percent of Cases with Late Stage - This is the number of late stages cases compared to the number of cases for all stages.


Other Notes


Line by Line Interpretation of the Report


US (SEER+NPCR)1


Alabama6


Alaska6


Arizona6


Arkansas6


California3


Colorado6


Connecticut3


Delaware6


District of Columbia6


Florida6


Georgia3


Hawaii3


Idaho3


Illinois3


Indiana6


Iowa3


Kansas6


Kentucky3


Louisiana3


Maine6


Maryland6


Massachusetts3


Michigan6


Minnesota6


Mississippi6


Missouri6


Montana6


Nebraska6


New Hampshire6


New Jersey3


New Mexico3


New York3


North Carolina6


North Dakota6


Ohio6


Oklahoma6


Oregon6


Pennsylvania6


Puerto Rico6


Rhode Island6


South Carolina6


South Dakota6


Tennessee6


Texas3


Utah3


Vermont6


Virginia6


Washington5


West Virginia6


Wisconsin6


Wyoming6


Nevada6

Notes:
Created by statecancerprofiles.cancer.gov on 06/09/2023 10:26 pm.

State Cancer Registries may provide more current or more local data.

Data cannot be shown for the following areas. For more information on what areas are suppressed or not available, please refer to the table.
Nevada

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
Data not available for this combination of data selections.

Source: SEER and NPCR data. For more specific information please see the table.

Interpret Rankings provides insight into interpreting cancer incidence statistics. When the population size for a denominator is small, the rates may be unstable. A rate is unstable when a small change in the numerator (e.g., only one or two additional cases) has a dramatic effect on the calculated rate.

Data not available for this combination of geography, cancer site, age, and race/ethnicity.

Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.